Moody's affirms 'A1' rating on Dana-Farber Cancer Institute

Moody's Investors Service affirmed its "A1" rating on Boston-based Dana-Farber Cancer Institute.

The rating affirmation is a result of several factors, including the institute's prominence in cancer research, strong fundraising capabilities, improved operating performance and long-standing relationships with other leading academic medical centers.

The outlook is stable.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars